ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores

Number of studies

Non-curative setting
5	17
4	95
3	127
2	34
1	19

Curative setting
A	40
C	2

ESMO-MCBS Scores by tumour type

Non-curative setting
Breast Cancer	29
Central Nervous System Malignancies	0
Endocrine Tumours	19
Gastrointestinal Cancers	53
Genitourinary Cancers	51
Gynaecological Malignancies	30
Head and neck cancer	6
Refractory NTRK fusion–positive cancers	2
Sarcoma	10
Skin Cancers	24
TMB-H solid tumours	1
Thoracic Malignancies	66
dMMR/MSI-H solid tumours	1

Curative setting
Breast Cancer	8
Central Nervous System Malignancies	1
Endocrine Tumours	0
Gastrointestinal Cancers	15
Genitourinary Cancers	4
Gynaecological Malignancies	0
Head and neck cancer	0
Refractory NTRK fusion–positive cancers	0
Sarcoma	2
Skin Cancers	9
TMB-H solid tumours	0
Thoracic Malignancies	3
dMMR/MSI-H solid tumours	0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

ESMO-MCBS V1.1 – Evaluation Forms

Evaluation form 1 Evaluation form 2a Evaluation form 2b Evaluation form 2c Evaluation form 3

Evaluation form 1 For new approaches to adjuvant therapy or new potentially curative therapies

Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:

Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:

Evaluation form 2c For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies

Evaluation form 3 For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR.

Column view

Tested Agent(s)	Combined Agent(s)	Control Arm	Treatment Setting	Tumour Type	Tumour Sub-type	Tumour Sub-group	Trial Name	Score	Scorecard
T-DM1	-	Lapatinib + capecitabine	HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane (extensive crossover)	Breast Cancer	Breast Cancer	HER2+	EMILIA	4	PRELIMINARY SCORE Non-Curative OS 6 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Pertuzumab	Trastuzumab + docetaxel	Trastuzumab + docetaxel + placebo	HER2-positive locally recurrent unresectable or metastatic breast cancer with no prior anti-HER2 therapy or ChT for metastatic disease	Breast Cancer	Breast Cancer	HER2+	CLEOPATRA	4	PRELIMINARY SCORE Non-Curative OS 5 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Lapatinib	Trastuzumab	Lapatinib	HER2-positive, hormone receptor-negative metastatic breast cancer after progression on prior trastuzumab + ChT regimen(s)	Breast Cancer	Breast Cancer	HER2+ HR-	EGF104900	4	PRELIMINARY SCORE Non-Curative OS 5 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Palbociclib	Fulvestrant	Fulvestrant + placebo	Hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer previously treated with endocrine therapy	Breast Cancer	Breast Cancer	HR+ HER2-	PALOMA-3	4	PRELIMINARY SCORE Non-Curative OS 6 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Ribociclib	Letrozole	Letrozole + placebo	First-line postmenopausal, hormone receptor-positive, HER2-negative advanced breast cancer	Breast Cancer	Breast Cancer	HR+ HER2-	MONALEESA-2	4	PRELIMINARY SCORE Non-Curative OS 5 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Panitumumab	FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)	FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)	1st line metastatic colorectal cancer (post hoc KRAS, NRAS BRAF WT)	Gastrointestinal Cancers	Colon and Rectal Cancer	-	PRIME	4	PRELIMINARY SCORE Non-Curative OS 5 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Cetuximab	FOLFIRI (folinic acid, 5-fluorouracil, irinotecan)	FOLFIRI (folinic acid, 5-fluorouracil, irinotecan)	1st line metastatic (post hoc KRAS, NRAS WT)	Gastrointestinal Cancers	Colon and Rectal Cancer	RAS-WT	CRYSTAL	4	PRELIMINARY SCORE Non-Curative OS 5 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Cetuximab	-	Best supportive care	Refractory metastatic KRAS-WT	Gastrointestinal Cancers	Colon and Rectal Cancer	KRAS-WT	-	4	PRELIMINARY SCORE Non-Curative OS 5 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Bevacizumab	Chemotherapy	Paclitaxel or topotecan or liposomal doxorubicin	Recurrent platinum-resistant ovarian cancer	Gynaecological Malignancies	Ovarian Cancer	-	AURELIA	4	PRELIMINARY SCORE Non-Curative OS 6 ADJUSTMENTS FINAL SCORE Non-Curative F1 2
Erlotinib	-	Carboplatin gemcitabine	1st line stage III or IV non-squamous, with EGFR mutation	Thoracic Malignancies	Non-small-cell Lung Cancer	EGFR+	OPTIMAL, CTONG-0802	4	PRELIMINARY SCORE Non-Curative OS 6 ADJUSTMENTS FINAL SCORE Non-Curative F1 2

1 of 10
2
3
4
5
...
10

Column view

	Tested Agent(s)	Combined Agent(s)	Control Arm	Treatment Setting	Tumour Type	Tumour Sub-type	Tumour Sub-group	Trial Name	Ref.	Score	esmo.mcbs.table.heading.visualisation	esmo.mcbs.table.heading.visualisation

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

The ESMO-MCBS Scorecards

Evaluation form 1 For new approaches to adjuvant therapy or new potentially curative therapies

Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:

Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:

Evaluation form 2c For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies

Evaluation form 3 For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR.

My watchlist

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE

PRELIMINARY SCORE

ADJUSTMENTS

FINAL SCORE